指南与共识术前评估与围术期医学疼痛医学

围术期丁丙诺啡管理:多学会专家组的教学综述与推荐

Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel.
指南 / 共识 · Reg Anesth Pain Med · 2021-08-12

该多学会工作组通过文献综述和改良德尔菲法形成共识,并采用美国预防服务工作组证据分级对推荐进行评级。核心推荐为:围术期不应常规停用丁丙诺啡,以降低阿片类药物使用障碍复发风险;对于未治疗的阿片类药物使用障碍伴急性疼痛患者,围术期可启动丁丙诺啡。

要点

  • 围术期不应常规停用用于治疗阿片类药物使用障碍的丁丙诺啡。
  • 未治疗的阿片类药物使用障碍伴急性疼痛患者,围术期可启动丁丙诺啡。
  • 启动丁丙诺啡可降低阿片类药物复发和过量死亡风险。

核心结论

  • 为降低阿片类药物使用障碍复发风险,围术期不应常规停用丁丙诺啡。
  • 围术期可对未治疗的阿片类药物使用障碍伴急性疼痛患者启动丁丙诺啡,以降低阿片类药物复发和过量死亡风险。

研究设计与样本

  • 由美国区域麻醉与疼痛医学学会、美国麻醉医师学会、美国疼痛医学学会、美国成瘾医学学会和美国卫生系统药师学会董事会批准成立多学会阿片类药物使用障碍工作组。
  • 工作组进行了广泛的文献检索,纳入多种研究类型并进行质量评价。
  • 采用改良德尔菲法评估文献和专家意见,所有声明和推荐均达成100%共识,并由委员会成员使用美国预防服务工作组证据分级指南进行分级。
  • 除共识推荐外,还对丁丙诺啡的药理学和法律 statute 进行了叙述性概述。

主要发现

  • 确定了两个核心主题用于制定推荐,共识目标为>75%,但工作组在两个主题上均达成100%共识。
  • 具体主题包括:(1) 为医生提供围术期接受丁丙诺啡治疗阿片类药物使用障碍患者的管理推荐;(2) 为医生提供围术期对疑似阿片类药物使用障碍患者启动丁丙诺啡的推荐。

关键数值与推荐

  • 围术期不应常规停用丁丙诺啡(基于100%共识的推荐)。
  • 围术期可对未治疗的阿片类药物使用障碍伴急性疼痛患者启动丁丙诺啡(基于100%共识的推荐)。

临床怎么用

  • 麻醉科和疼痛科医生可在围术期考虑对疑似阿片类药物使用障碍患者启动丁丙诺啡,作为通往综合治疗的桥梁。
  • 对于正在接受丁丙诺啡治疗阿片类药物使用障碍的患者,围术期应继续使用而非常规停用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The past two decades have witnessed an epidemic of opioid use disorder (OUD) in the USA, resulting in catastrophic loss of life secondary to opioid overdoses. Medication treatment of opioid use disorder (MOUD) is effective, yet barriers to care continue to result in a large proportion of untreated individuals. Optimal analgesia can be obtained in patients with MOUD within the perioperative period. Anesthesiologists and pain physicians can recommend and consider initiating MOUD in patients with suspected OUD at the point of care; this can serve as a bridge to comprehensive treatment and ultimately save lives. METHODS: The Board of Directors of the American Society of Regional Anesthesia and Pain Medicine, American Society of Anesthesiologists, American Academy of Pain Medicine, American Society of Addiction Medicine and American Society of Health System Pharmacists approved the creation of a Multisociety Working Group on Opioid Use Disorder, representing the fields of pain medicine, addiction, and pharmacy health sciences. An extensive literature search was performed by members of the working group. Multiple study types were included and reviewed for quality. A modified Delphi process was used to assess the literature and expert opinion for each topic, with 100% consensus being achieved on the statements and each recommendation. The consensus statements were then graded by the committee members using the United States Preventive Services Task Force grading of evidence guidelines. In addition to the consensus recommendations, a narrative overview of buprenorphine, including pharmacology and legal statutes, was performed. RESULTS: Two core topics were identified for the development of recommendations with >75% consensus as the goal for consensus; however, the working group achieved 100% consensus on both topics. Specific topics included (1) providing recommendations to aid physicians in the management of patients receiving buprenorphine for MOUD in the perioperative setting and (2) providing recommendations to aid physicians in the initiation of buprenorphine in patients with suspected OUD in the perioperative setting. CONCLUSIONS: To decrease the risk of OUD recurrence, buprenorphine should not be routinely discontinued in the perioperative setting. Buprenorphine can be initiated in untreated patients with OUD and acute pain in the perioperative setting to decrease the risk of opioid recurrence and death from overdose.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Kohan L, Potru S, Barreveld AM, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021. PMID: 34385292. doi:10.1136/rapm-2021-103007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。